Impulsivity and Its Relationship With Lisdexamfetamine Dimesylate Treatment in Binge Eating Disorder.

High trait impulsivity is thought to contribute to the sense of loss of control over eating and impulses to binge eat experienced by those with binge eating disorder (BED). Lisdexamfetamine dimesylate (LDX), a drug approved for treatment of moderate to severe BED, has been shown to decrease impulsive features of BED. However, the relationship between LDX-related reductions of binge eating (BE) episodes and impulsivity has not yet been explored. Forty-one adults aged 18-40years with moderate to severe BED completed questionnaires and tasks assessing impulsivity at baseline and after 8weeks of 50-70mg of LDX. Twenty age-matched healthy controls were also assessed at two timepoints for normative comparison. Data were analysed using linear mixed models. BED participants exhibited increased self-reported motor, non-planning, cognitive and food-related impulsivity relative to controls but no differences in objective task-based measures of impulsivity. Food-related and non-planning impulsivity was significantly reduced by LDX, but not to normative levels. Individuals with higher baseline levels of motor and non-planning impulsivity, and loss of control over eating scores experienced the greatest reduction in BE frequency after 8weeks of LDX. Further, there were significant associations between the degree to which subjective loss of control over eating, non-planning impulsivity and BE frequency reduced after 8weeks of LDX. These data suggest that specific subjective measures of impulsivity may be able to predict who will have the greatest benefit from LDX treatment and that reductions in BE frequency may be moderated by concurrent reductions in non-planning impulsivity.

Informations de copyright

Copyright © 2021 Griffiths, Aparício, Braund, Yang, Harvie, Harris, Hay, Touyz and Kohn.

Déclaration de conflit d'intérêts

KG has been the recipient of honoraria from Shire (Takeda group of companies) for public speaking engagements. PH receives/has received sessional fees and lecture fees from the Australian Medical Council, Therapeutic Guidelines publication, and HETI (New South Wales and the former NSW Institute of Psychiatry) and royalties/honoraria from Hogrefe and Huber, McGraw Hill Education, and Blackwell Scientific Publications, Biomed Central and PlosMedicine, and she has received research grants from the NHMRC and ARC. She is Chair of the National Eating Disorders Collaboration Steering Committee in Australia (2019-) and was Member of the ICD-11 Working Group for Eating Disorders and was Chair Clinical Practice Guidelines Project Working Group (Eating Disorders) of RANZCP (2012–2015). She has prepared a report under contract for Takeda (formerly Shire) Pharmaceuticals in regard to binge eating disorder (July 2017) and is a consultant to Takeda Pharmaceuticals. All views in this paper are her own. ST has been the recipient of honoraria from Shire (Takeda group of companies) for public speaking engagements and commissioned reports. He has been the Chair of their Clinical Advisory Group for binge eating disorder. He receives honoraria for books/book chapters from McGraw Hill. Hogrefe and Huber and Taylor and Francis. He is the co-director of the Inside Out Institute at the University of Sydney. ST is a mental health consultant to BUPA. He is a member of the Department of Health Technical Advisory Group for Eating Disorders (Commonwealth Government). MK has been the recipient of honoraria from Shire (Takeda group of companies) for public speaking engagements. LA, TB, JY, GH and AH have no potential conflicts of interest to declare.